CONNECT WITH US:
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal
Jun 17, 2020 18:00 JST
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that their COVID-19 research with Global Research and Discovery Group Sciences ("GRDG"), conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc. ("Vilotos"), was published in the peer-reviewed scientific journal Molecules on June 11, 2020.
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts
Jun 01, 2020 13:00 JST
SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary, Impact Biomedical Inc., would like to update its stakeholders on its suite of antiviral and medical technologies.
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts
Apr 24, 2020 10:00 JST
SGX-listed Singapore eDevelopment Ltd's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced recently that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical's effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million).
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak
Mar 18, 2020 11:00 JST
Singapore Exchange-listed Singapore eDevelopment Limited has announced that its wholly-owned U.S. biomedical subsidiary, Impact BioMedical, Inc., has, through its scientific research partner, GRDG Sciences, LLC. ("GRDG"), recently conducted molecular docking studies, utilizing advanced computational models, which indicate Linebacker and Equivir successfully inhibit infection of SARS-CoV-2, the virus responsible for the COVID-19 outbreak.
Global BioLife to Present 3F Antimicrobial Fragrance at 2020 ASM Biothreats
Nov 15, 2019 02:00 JST
Global BioLife Inc, the U.S.subsidiary of SGX-listed Singapore eDevelopment Ltd (SeD), will present research on its 3F Antimicrobial Fragrance as a new method to prevent and treat Tuberculosis at the 2020 ASM Biothreats conference, taking place from 28 to 30 January 2020 in Arlington, Virginia.
Global BioLife to present Functional Fragrance Formula at the American Society for Microbiology's Biothreats Conference as a New Method to Prevent and Treat Tuberculosis
Oct 29, 2019 09:00 JST
SGX-listed Singapore eDevelopment Limited ("SeD", SGX:40V) wishes to announce that its biomedical subsidiary incorporated in Nevada, Global BioLife Inc. ("Global BioLife") will be presenting its research on its Functional Fragrance Formula ("3F") against tuberculosis at the 2020 American Society for Microbiology ("ASM") Biothreats Conference.
Global BioLife unveils naturally modified Laetose at Harvard Global Catalyst Health Summit
Jul 24, 2019 15:00 JST
SGX-listed Singapore eDevelopment Ltd (SeD) is pleased to announce the results of clinical trials conducted on Laetose(TM), developed by its U.S. biomedical subsidiary, Global BioLife Inc. ("Global BioLife").
Global BioLife's 3F Mosquito Repellent Formula performs well in Independent Testing
Jun 12, 2019 14:00 JST
SGX-listed Singapore eDevelopment Ltd (SeD) wishes to announce that its U.S. biomedical subsidiary Global BioLife Inc. has independently tested its new 3F Mosquito Formula which performs well against mosquitoes for six (6) to eight (8) hours.
Global BioLife's 3F Antimicrobial Fragrance shows Efficacy against Tuberculosis
Jan 28, 2019 12:00 JST
SGX-listed Singapore eDevelopment Ltd (SeD) is pleased to announce that its U.S. biomedical subsidiary Global BioLife Inc. has developed 3F Antimicrobial Fragrance, which shows efficacy against tuberculosis.
Singapore eDevelopment's Global BioLife to present Parkinson's Research at Neuroscience 2018
Nov 07, 2018 19:00 JST
Singapore eDevelopment (SGX: 40V) ("SeD") subsidiary, Global BioLife Inc. is pleased to announce that research of their promising drug platform, Linebacker, will be presented at Neuroscience 2018, the Annual Meeting for the International Society for Neuroscience (SfN) in San Diego, California.
Singapore eDevelopment Limited Announces Corporate and Business Update
Jun 18, 2018 19:00 JST
The Board of Directors of Singapore eDevelopment Limited wishes to provide shareholders an update on the Group's operations.
Singapore eDevelopment's Global BioLife develops Low Glycemic Modified Sugar
May 31, 2018 18:00 JST
Singapore Exchange-listed Singapore eDevelopment Limited ("SeD") announced today that its U.S. biomedical subsidiary, Global BioLife, Inc. ("Global BioLife"), has developed a low glycemic index, naturally modified sugar - Laetose - which has the potential to affect the world's sugar market.
Singapore eDevelopment's Global BioLife confirms LB2 efficacy against Ebola
Mar 01, 2018 14:00 JST
Singapore eDevelopment (SGX: 40V; SeD) is pleased to announce biomedical subsidiary Global BioLife, Inc. has completed the initial Zaire Ebola research portion for the study of new anti-viral drug LB2, part of its new universal therapeutic drug platform, Linebacker.
Singapore eDevelopment's Global BioLife confirms 100% Repellency of 3F Mosquito Fragrance
Nov 01, 2017 18:00 JST
SGX-listed Singapore eDevelopment Ltd (SeD) announced today that its U.S. biomedical subsidiary, Global BioLife Inc. has completed development and testing of mosquito deterring technologies including fragrances, paints, and fabric.
Singapore eDevelopment's Global BioLife develops Low-GI Modified Sugar
Oct 24, 2017 18:00 JST
SGX-listed Singapore eDevelopment Ltd ("SeD") announced today that its U.S. biomedical subsidiary, Global BioLife Inc. has developed a breakthrough low-calorie, low glycemic index, natural, modified sugar Laetose -- which has the potential to affect the world's sugar market.
Singapore eDevelopment's Global BioLife and Chemia Corp. to develop 3F suite of Functional Fragrances
Aug 15, 2017 19:00 JST
Singapore eDevelopment Ltd (SeD; SGX:SGE) has announced that its indirect subsidiary, Global BioLife Inc., is collaborating with U.S.-based Chemia Corporation to develop specialised fragrances which can counter mosquito-borne diseases, diminish stress and anxiety, and act in anti-viral medical applications.
First-Year Performance of Global Systematic Multi-Strategy Fund
Jun 15, 2017 10:15 JST
The Board of Directors of Singapore eDevelopment Ltd ("SeD") wishes to announce that its Global Systematic Multi-Strategy Fund ("GSMS Fund") managed by Hengfai Asset Management Pte Ltd ("HFAM"), a wholly owned subsidiary of SeD's investment-arm SeD Capital Pte Ltd, achieved a gross and net return of 15% and 10%, respectively, in its first year of operation.
Singapore eDevelopment Subsidiary Initiates Research on New Universal Drug Platform
May 22, 2017 11:00 JST
Singapore eDevelopment Limited ("SeD") subsidiary Global BioLife Inc. has initiated advanced research of a new universal therapeutic drug platform, known as Linebacker, to combat a range of diseases including Alzheimer's, diabetes and cancer.
TOYOTA GAZOO Racing WRC Challenge Program
Jul 10, 2020 17:22 JST
Hitachi ABB Power Grids India Wins INR 120 Crore Order for Indian Railways Electrification
Jul 10, 2020 09:07 JST
NEC Solution Innovators Establishes "FonesLife," a healthcare business company that contributes to extending healthy life expectancy
Jul 09, 2020 14:34 JST
Biogen Completes Submission of Biologics License Application to FDA for Aducanumab as a Treatment for Alzheimer's Disease
Jul 09, 2020 12:20 JST
Eisai and Merck Receive Complete Response Letter for LENVIMA (lenvatinib) plus KEYTRUDA (pembrolizumab) Combination as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Jul 09, 2020 12:11 JST
"Corolla Meets SUV"--Toyota Unveils Corolla Cross in Thailand, The New Compact SUV with Strength and Functionality to the Corolla Series
Jul 09, 2020 10:59 JST
Eisai: New Drug Application for In-House Developed New Anti-insomnia Drug Dayvigo Accepted in Hong Kong
Jul 08, 2020 14:33 JST
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tazemetostat for EZH2 Gene Mutation-Positive Follicular Lymphoma
Jul 08, 2020 14:16 JST
HSPP Announces Corporate Name Change to Honda India Power Products Limited
Jul 07, 2020 14:37 JST
Lexus Premieres New LS
Jul 07, 2020 13:31 JST
HOYA and Hitachi Announce Long Term Technical Collaboration and Supply Agreement Related to Endoscopic Ultrasound Systems
Jul 06, 2020 17:39 JST
Announcement of Absorption-type Merger (Simplified Merger and Short-form Merger) of DENSO IT Solutions Inc.
Jul 06, 2020 16:34 JST
JGA North is Ready for Service
Jul 06, 2020 15:30 JST
Aichi Cancer Center and NEC Launch Joint Research on Fundamental Study Aimed at Advanced Cancer Immunotherapy
Jul 06, 2020 15:11 JST
Toyota Reproduces and Sells Spare Parts for 2000GT
Jul 06, 2020 13:37 JST
Fujitsu Embarks Towards 'New Normal', Redefining Working Styles for its Japan Offices
Jul 06, 2020 11:47 JST
Eisai to Launch In-House Developed New Anti-insomnia Drug Dayvigo (Lemborexant) with Indication for Insomnia in Japan
Jul 06, 2020 09:33 JST
Eisai: New Fine Granule Formulation of Anti-epileptic Drug Fycompa Launched in Japan
Jul 06, 2020 09:05 JST
NEC and JAMSTEC Develop AI-based System for Measuring Microplastics in the Ocean
Jul 03, 2020 11:30 JST
Fujitsu Revamps Corporate Philosophy 'FUJITSU Way' to Achieve Our Purpose
Jul 01, 2020 14:22 JST
More Latest Release >>